Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fidelion Diagnostics
Singapore
- Ownership
- Private
- Development stage
- Other
01
Overview
Fidelion Diagnostics recently launched the VitaGuard™ platform, achieving industry-leading sensitivity in liquid biopsy MRD detection. Clinical validation has demonstrated detection of molecular residual disease months to years before conventional imaging, enabling earlier intervention for cancer recurrence and data-driven prevention efforts[1][5][7].
- Therapeutic areas
- Oncology
- Modalities
- DeviceDigital diagnostic platformAI-driven diagnostics
- Industry
- Molecular Diagnostics
02
Partnerships
BioNexus Gene Lab Corp. (BGLC)
Beyond the preview
Go deeper on Fidelion Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fidelion Diagnostics.